[ET Net News Agency, 15 September 2021] Livzon Pharmaceutical Group Inc. (01513) said
its subsidiary Livzon Group Xinbeijiang Pharmaceutical Manufacturing Inc. has recently
received the Notice of Acceptance (acceptance No: CXSL2101318 Guo) issued by China
National Medical Products Administration (NMPA). The application for the clinical trial of
a domestically manufactured drug, the Semaglutide Injection, was accepted by NMPA.
It is a novel and long-sustained glucagon-like peptide 1 (GLP-1) receptor agonist and is
used for the blood sugar control of adult patients with type 2 diabetes who has received,
on the basis of diet control and exercise, the treatment of metformin and/or sulfonylureas
but failed to control their blood sugar, and for reducing the risk of major adverse
cardiovascular events (such as cardiovascular death, non-fatal myocardial infarction, or
non-fatal stroke) in adult patients with type 2 diabetes as well as cardiovascular
diseases. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
25.750 +0.100 (+0.390%) Others
15/09/2021 10:11
Livzon Pharma (01513) unit gets notice of acceptance
| Remark: | Real time quote last updated: 23/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |